- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04567927
Prevalence and Risk Factors for Venous Thromboembolic Events in Critically Ill Patients With COVID-19
September 25, 2020 updated by: Chiesa Alessandro Felice
Prevalence and Risk Factors for Venous Thromboembolic Events in Critically Ill Patients With SARS-CoV-2 Infection
The purpose of the study is to assess the frequency of the occurrence of a venous thrombosis in patients with the new Coronavirus disease, who are admitted to the Intensive Care Unit for impending respiratory failure requiring intubation and mechanical ventilation.
Furthermore, the investigators aim at identifying potential risk factors for thrombosis and death.
Study Overview
Detailed Description
Symptomatic infection with the severe acute respiratory syndrome coronavirus 2 ranges from mild to critical spectrum.
About 80% of laboratory confirmed infections presented with mild symptoms, usually not requiring hospitalization.
Critical disease requiring respiratory and/or circulatory support was reported in 5% of the subjects.
Acute respiratory distress syndrome represents the most common complication in patients with severe disease.
Several cases of venous thromboembolism in patients with laboratory confirmed infection have been reported, but it is unclear if this occurrence is higher in this specific patients' population.
The purpose of the present study is to assess the prevalence of deep venous thrombosis in patients infected with SARS-CoV-2 admitted to the Intensive care Unit requiring invasive mechanical ventilation using vein ultrasonography.
Study Type
Observational
Enrollment (Actual)
80
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ticino
-
Bellinzona, Ticino, Switzerland, 6500
- Ospedale Regionale di Bellinzona e Valli
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
All consecutive adult patients with laboratory confirmed SARS-CoV-2 infection admitted to the Intensive Care Unit requiring invasive respiratory support
Description
Inclusion Criteria:
- patients admitted to the Intensive Care Unit
- laboratory confirmed SARS-CoV-2 infection
- invasive respiratory support
Exclusion Criteria:
- none
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Period prevalence of deep vein thrombosis (DVT)
Time Frame: From date of inclusion in the study until the date of development of a DVT, date of death from any cause, or date of discharge from the ICU, whichever came first, assessed up to 3 months
|
Percent (%) of patients with a DVT
|
From date of inclusion in the study until the date of development of a DVT, date of death from any cause, or date of discharge from the ICU, whichever came first, assessed up to 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020 Apr 7;323(13):1239-1242. doi: 10.1001/jama.2020.2648. No abstract available.
- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24. Erratum In: Lancet. 2020 Jan 30;:
- Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061-1069. doi: 10.1001/jama.2020.1585. Erratum In: JAMA. 2021 Mar 16;325(11):1113.
- Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, Wu Y, Zhang L, Yu Z, Fang M, Yu T, Wang Y, Pan S, Zou X, Yuan S, Shang Y. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24. Erratum In: Lancet Respir Med. 2020 Apr;8(4):e26.
- Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, Cereda D, Coluccello A, Foti G, Fumagalli R, Iotti G, Latronico N, Lorini L, Merler S, Natalini G, Piatti A, Ranieri MV, Scandroglio AM, Storti E, Cecconi M, Pesenti A; COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020 Apr 28;323(16):1574-1581. doi: 10.1001/jama.2020.5394. Erratum In: JAMA. 2021 May 25;325(20):2120.
- Wang T, Chen R, Liu C, Liang W, Guan W, Tang R, Tang C, Zhang N, Zhong N, Li S. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. Lancet Haematol. 2020 May;7(5):e362-e363. doi: 10.1016/S2352-3026(20)30109-5. Epub 2020 Apr 9. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 3, 2020
Primary Completion (Actual)
May 28, 2020
Study Completion (Actual)
May 28, 2020
Study Registration Dates
First Submitted
September 18, 2020
First Submitted That Met QC Criteria
September 25, 2020
First Posted (Actual)
September 29, 2020
Study Record Updates
Last Update Posted (Actual)
September 29, 2020
Last Update Submitted That Met QC Criteria
September 25, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-01266
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS Virus
-
Bangkok Metropolitan Administration Medical College...Completed
-
Hospital Departamental de VillavicencioCooperative University of Colombia; Clinica Primavera; Clínica Meta; Grupo de Investigación...WithdrawnSARS-CoV 2 | COVID | SARS (Severe Acute Respiratory Syndrome) | SARS (Disease) | SARS Pneumonia
-
University Hospital, Basel, SwitzerlandsciCORE University of Basel; Leonhard Med IT ETH Zurich; Swiss Institute of BioinformaticsRecruitingSARS Coronavirus (SARS-CoV-2) InfectionSwitzerland
-
Versailles HospitalUnknown
-
BioNTech SECompletedCOVID-19 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | SARS (Disease)United States, Germany, Turkey, South Africa
-
Collegium Medicum w BydgoszczyRecruitingSARS-CoV2 Infection | SARS-CoV2 AntibodiesPoland
-
National Institute of Allergy and Infectious Diseases...Completed
-
Collegium Medicum w BydgoszczyActive, not recruitingSARS-CoV2 Infection | SARS-CoV2 AntibodiesPoland
-
Valneva Austria GmbHCompletedSARS-CoV-2 Virus InfectionUnited Kingdom
-
St. Olavs HospitalThe Research Council of Norway; Helse Nord-Trøndelag HF; Alesund Hospital; Namsos... and other collaboratorsCompletedSARS-CoV-2 Acute Respiratory Disease | SARS-CoV-2 Sepsis | SARS CoV 2 InfectionNorway
Clinical Trials on Ultrasonography
-
Benha UniversityUnknownPostmenopausal BleedingEgypt
-
Ankara City Hospital BilkentNot yet recruitingObstructive Sleep Apnea | Respiratory Complication | Airway Edema
-
Waldfriede HospitalRecruiting
-
Cantonal Hosptal, BasellandInsel Gruppe AG, University Hospital BernRecruitingObstructive Sleep Apnea | Sleep-Disordered BreathingSwitzerland
-
Cairo UniversityRecruitingHypertension in PregnancyEgypt
-
Sohag UniversityNot yet recruitingHepatic Steatosis and Fibrosis in Rheumatoid Arthritis Patients
-
Assiut UniversityNot yet recruitingPlacenta Previa | Vaginal Bleeding | Antepartum Hemorrhage
-
Assiut UniversityNot yet recruitingPediatric Lymphoma
-
Zeynep Kamil Maternity and Pediatric Research and...RecruitingEndometriosis, Rectum | ULTRASONOGRAPHYTurkey
-
Stanford UniversityRecruiting